Herpes simplex virus type 1 thymidine kinase (HSV1-tk) mutant sr39 (HSV1-sr39tk)

HSV1-sr39 thymidine kinase is a mutant variant of the Herpes Simplex Virus type 1 thymidine kinase (HSV1-tk) enzyme, specifically engineered to enhance its catalytic efficiency toward certain nucleoside analogs. This super-mutant contains five amino acid substitutions (L159I, I160F, F161L, A168F, and L169M) that significantly decrease the Michaelis constant (Km) for substrates like ganciclovir and penciclovir, making it a more potent tool for gene therapy and molecular imaging [4, 8, 19]. In the context of suicide gene therapy, the enzyme is expressed in target cells (e.g., cancer cells) to convert non-toxic prodrugs into cytotoxic triphosphates that inhibit DNA polymerase and trigger apoptosis [7, 15, 18]. Additionally, HSV1-sr39tk serves as a widely used Positron Emission Tomography (PET) reporter gene, where its ability to sequester radiolabeled probes like [18F]FHBG allows for the non-invasive visualization of gene expression and cell trafficking in vivo [1, 2, 6]. Its improved sensitivity over the wild-type enzyme allows for the use of lower prodrug doses, potentially reducing systemic side effects such as myelosuppression [4, 16]. The enzyme's broad substrate specificity is a key feature, allowing it to process both pyrimidine and purine analogs that are not efficiently phosphorylated by mammalian kinases [12, 17]. This selectivity ensures that the cytotoxic effects are largely confined to the cells expressing the viral enzyme [15, 18].

Other names

sr39HSV1-sr39TKmutant HSV1-tksuper-mutant thymidine kinasesr39TK

The enzyme catalyzes the initial phosphorylation of nucleoside analogs (prodrugs) into monophosphates. These are subsequently converted into cytotoxic triphosphates by endogenous host cell kinases. The resulting triphosphates act as competitive inhibitors of DNA polymerase and are incorporated into nascent DNA strands, causing premature chain termination and inducing apoptosis.